Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-05

Clinical Trial Update: Reversing Ticagrelor's Effects With Fresh Platelets [Phase 4]

View source ↗

Summary

A Phase 4 trial assesses whether transfusing fresh platelets can reverse the antiplatelet effects of ticagrelor in patients with coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BRILINTA (ticagrelor)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED | Results posted: 2017-12-05